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Introduction
Rubella virus infection is sub-clinical in approximately 
50% of cases and, when symptoms are present, they are 
usually quite mild, including inflammation of the retronu-
cal lymph nodes and maculopapular rash, which may be 
preceded by mild catarrhal symptoms. The rash is immu-
nologically mediated and coincides with the development 
of specific anti-rubella antibodies [1-3]. Rubella infection 
acquired during the first trimester of pregnancy can cause 
multifactorial foetal damages, that result from a combina-
tion of direct rubella virus cytopathic effect and on the 
induction of apoptosys. Moreover placental infection that 
occurs during maternal viraemia, causes focally distrib-
uted necrotic areas in the chorionic villae epithelium and 
in the endothelial cells of its capillaries [4].
Up to 90% of infants born from mothers infected during 
the first 11 weeks of gestation develop a pattern of birth 
defects called Congenital Rubella Syndrome/ Infection 
(CRS/CRI) [5], responsible, in early infancy, of glau-
coma, pigmentary retinopathy, ventricular septal defect, 
pulmonary artery stenosis ecc. The risk of abnormalities 
decrease if the infection occurs after 12 week of gesta-
tion and after 16 weeks the incidence of foetal damage 
is less than 2%. Deafness and retinopathy are frequently 
the only manifestation of congenital infections in par-
ticular if it’s subclinical.
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The high public health relevance of rubella is due to 
the theratogenic effects resulting from virus infection 
during pregnancy. An high vaccination coverage could 
prevent the indigenous rubella virus circulation and so 
reduce the wide burden of the disease.
In 2002, World Health organization (WHo) Regional 
office for Europe developed the first strategic plan for 
rubella elimination and 3 years later a new plan was 
implemented with the aim to eliminate endemic rubella 
and reduce CRS incidence < 1 case per 100.000 live 
births by 2010 [8]. In Italy the National Plan for elimi-
nation of measles and congenital rubella, was approved 
on November 2003 [9, 10]. The goal of the plan was to 
eliminate measles and reduce the incidence of CRS cas-
es as recommended by WHo, to reach national vaccine 
coverage of at least of 95% in 24 months children to 
ensure an high immunity level among women of child-
bearing age. Notification of rubella infection during 
pregnancy and CRS/CRI were mandatory since 1 Janu-
ary 2005. Furthermore, the national plan established a 
regional laboratory network with the aim to improve the 
diagnostic ability.
In this article, results of 21-month virological sur-
veillance conducted in Liguria, an Italian region of 
1,700,000 inhabitants and about 11,000 newborn/year, 
are presented.
Summary 
Introduction.	 Rubella	 is	 generally	 a	 mild	 rush	 fever	 disease	
when	 acquired	 in	 childhood,	 but	 when	 infection	 occurs	 dur-
ing	 the	 first	months	 of	 pregnancy,	 high	 risk	 of	 trans-placental	
transmission	 to	 the	 foetus	 and	 of	 congenital	 anomalies	 exists.	
In	November	2003,	a	National	Plan	for	measles	and	congenital	
rubella	elimination	was	approved	in	Italy.	The	aim	was	to	reduce	
and	maintain	Congenital	Rubella	Syndrome	incidence	lower	than	
1	 case	per	100.000	 live	births/year	by	2007.	Since	 June	2006,	
Liguria	Administrative	Region	 recognized	U.O.	Hygiene,	“San	
Martino”	 University	 Hospital,	 Genoa,	 as	 regional	 reference	
laboratory	 for	diagnosis	of	 rubella	 infection	during	pregnancy	
and	post-partum.
Methods. Twenty-one-month	 virological-surveillance	 results	
between	April	2007	and	December	2008	were	reported	in	terms	
of	demographic	data,	risk	 factors,	access	reasons,	clinical	pic-
ture,	vaccination,	previous	rubella	disease,	laboratory	results	of	
pregnant	women	and	newborns.
Results and conclusion.	Since	the	beginning	of	surveillance,	65	
pregnant	women	with	suspected	virus	infection	and	18	newborns	
with	 suspected	congenital	 rubella	were	 followed	up.	The	results	
of	 laboratory	 surveillance	 highlighted	 (i)	 the	 importance	 of	 an	
early	screening,	(ii)	the	suboptimal	specificity	of	chemiluminescent	
assays,	that	often	yield	false	positive	IgM	results	and	(iii)	the	fun-
damental	role	of	second-level	laboratory	to	confirm	the	serologi-
cal	diagnosis	and	to	detect	the	virus	by	molecular	techniques.	
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Materials and method
Role of the laboratory
According to WHo recommendation the main objec-
tives of rubella reference laboratory were (i) to develop 
protocols for the laboratory diagnosis of rubella and 
provide the necessary support, (ii) to provide resources 
and facilities for staff training and (iii) to confirm the 
clinical diagnosis of clinically suspected cases using 
IgM ELISA assays to help in early detection of CRI/
CRS.
Clinical diagnosis of rubella not always is possible, sin-
ce the clinical signs are transient and can be confused 
with measles or parvovirus B19 infection [4], moreover 
50% of rubella infections may be subclinical. Thus, 
laboratory confirmation by serological tests is essential. 
Detection of virus specific IgM in serum during pre-
gnancy is the most commonly used method to confirm 
the infection occurrence. 
The IgM detection chemiluminescent assays routinely 
used by first level laboratories present some limitations: 
firstly, specific IgM antibodies mostly persist for 6-12 
weeks, and it’s not possible to distinguish between a 
recent primary rubella infection or a re-infection; secon-
dly, false positive results may occur due to cross-reac-
ting IgM antibodies or to rheumatoid factor. Full clinical 
and epidemiological picture must be considered for the 
correct interpretation of the IgM detection assay.
Blood samples that result positive for IgM in early de-
tection during pregnancy, should be sent to the Regional 
Reference Laboratory, where second level diagnosis is 
performed. It includes: (i) high specific immunoenzy-
matic assays for IgM detection and quantitation, (ii) 
test for IgG and IgG avidity evaluation, (iii) storage of 
all available consecutive samples for the evaluation of 
antibody kinetics and (iv) nucleic acid-based assay and 
culture for viral detection and isolation, to confirm if an 
infection has been recently acquired. In particular, RT-
PCR to detect rubella virus directly from clinical mate-
rial (pharyngeal swabs, amnios and urine) is highly sen-
sitive and specific; sensitivity of detection of viral RNA 
in amniotic fluid varies from 87 to 100% [11, 12]. 
Diagnosis of CRS in newborn children focuses on virus 
isolation from urine samples and on the demonstration 
of virus specific IgM, which can be detected in almost 
100% of infected infants 0-3 years of age and progres-
sively decline to less than 50% at 12 months of age. 
Some infected newborns do not produce IgM at birth 
and IgM false negative results may occur despite the 
high specificity of immunoenzymatic assay. This could 
be the consequence of the fact that congenital infected 
neonates have high Rubella specific IgG titers of both 
self and maternal origin that tend to compete with IgM 
antibodies for binding. In these cases diagnosis is ba-
sed on the evaluation of IgG kinetics and IgG avidity 
during the first months of life and by detection of viral 
RNA in clinical samples as urine and oral fluid by RT-
PCR [13, 14]. 
Case definition
Rubella infection
All suspected cases of rubella during pregnancy and 
congenital rubella, that has been reported by physicians 
to the local health authorities, are classified into one of 
this categories:
(i) suspected	 case. Any generalized rash illness of 
acute onset; any positive result of rubella specific IgM 
in patient serum even in absence of clinical symptom; 
contact (person to person) with a confirmed patient or a 
person with a rash illness suspected of being rubella;
(ii) probable	case. A case that meets the clinical case de-
finition of acute onset, generalized maculopapular rush, 
temperature > 37,2°C and at least one of the following 
signs: lymphoadenopathy, arthralgia/ arthritis or congiun-
tivitis, also in absence of laboratory confirmation.
iii) confirmed	case. A case that is laboratory confirmed 
or that meets the clinical case definition and is epide-
miologically linked to a laboratory confirmed case [9].
Congenital Rubella
(i) Suspected	 case: Any infant less than one year of 
age in whom a health worker suspects CRS. A health 
worker should suspect CRS when an infant aged 0-11 
months presents with heart disease and/or suspicion of 
deafness and/or one or more of the following eye signs: 
white pupil (cataract), diminished vision, pendular mo-
vement of the eyes (nystagmus), squint, smaller eye ball 
(microphthalmus), or larger eye ball (congenital glauco-
ma). A health worker should also suspect CRS when an 
infant’s mother has a history of suspected or confirmed 
rubella during pregnancy, even when the infant shows 
no signs of CRS.
(ii) Clinically	 confirmed	 case: An infant in whom a 
qualified physician detects at least two of the complica-
tions listed in (a) below or one in (a) and one in (b): (a) 
Cataract(s), congenital glaucoma, congenital heart di-
sease, loss of hearing, pigmentary retinopathy; (b) Pur-
pura, splenomegaly, microcephaly, mental retardation, 
meningocephalitis, radiolucent bone disease, jaundice 
that begins within 24 hours after birth
(iii) Laboratory	 confirmed	 case: An infant with clini-
cally confirmed CRS who has a positive blood test for 
rubella-specific IgM (almost 100% of such infants are 
positive at the age of 0-5 months; 60% are positive at 6-
11 months; 50% at 12 months). Where special laboratory 
resources are available, the detection of rubella virus in 
specimens from the pharynx or urine of an infant with 
suspected CRS provides laboratory confirmation of CRS 
(60% of such infants shed rubella virus at the age of 1-4 
months; 30% at 5-8 months: 10% at 9-11 months).
(iiii) Congenital	rubella	infection	(CRI): If a mother has 
suspected or confirmed rubella in pregnancy, her infant 
should have a rubella-specific IgM blood test. An infant 
who does not have clinical signs of CRS but who has a 
positive rubella-specific IgM test is classified as having 
congenital rubella infection (CRI).
The diagnosis of rubella infection during pregnancy 
requires one or more of the samples: maternal blood, 
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foetal blood, urine, throat swab, amniotic liquid, liquor, 
saliva. Biological samples useful in case of CRS/CRI 
diagnosis are: blood, urine, throat swab, liquor, saliva
Laboratory investigations
Samples were collected from clinicians participating to 
the surveillance network and sent to the Reference La-
boratory to confirm rubella virus infection in pregnant 
women if they have (i) generalized maculopapular rash, 
(ii) serologic test for immunoglobulin M (IgM) antibody 
positive, (iii) immunoglobulin G (IgG) seroconvertion 
and/or (iv) a link with a confirmed case (a contact of at 
least 15 minutes or face-to-face).
As regard as newborn children, laboratory diagnosis of 
CRS/CRI is required (i) for all infants born to mothers 
with suspected or confirmed infection and (ii) if there 
are clinical manifestations or anomalies consistent with 
congenital viral infection.
Laboratory diagnosis of congenital rubella syndrome is 
based on detection of specific immunoglobulin M and G 
(IgM and IgG) and evaluation of IgG avidity by means 
of enzyme-linked immunosorbent assay (ELISA), on vi-
ral growth by culture isolation and on detection of viral 
RNA using molecular test RT-PCR based.
In agreement with the WHo guidelines, in our protocol 
are reported criteria for: 
(i) Diagnosis during pregnancy:
• IgM or IgG seroconversion;
• IgM in presence of clinical diagnosis and/or low 
avidity IgG;
• at least 4 fold increase of IgG titer between 2 serum 
samples (the first one collected no more than 7-10 
days after a rash or after case contact and the second 
one at least 14 days after the first);
• viral growth on cell culture from urine, blood, throat 
swab or saliva collected from 7 days before until 14 
days after the rash;
• RT-PCR positive test in samples collected from 7 
days before until 14 days after a rash.
(ii) CRS: 
• detectable IgM in foetal blood since 20th week of 
pregnancy;
• RT-PCR positive test or viral growth from foetal 
blood or amniotic liquid, preferably collected 6 
weeks after seroconversion and/or at 22th week (this 
care reduces false-negative results).
(iii) CRI: 
• IgM positive in the first month of life;
• persistent high IgG titer (if the newborn was unin-
fected, each month the IgG titer decrease of 50% and 
is undetectable since the 6th month);
• RT-PCR or culture isolation positive.
In Figure 1 is reported the algorithm adopted for the 
rubella infection and CRS/CRI diagnosis. 
Reference laboratory assays
Rubella-virus specific IgM, IgG and IgG avidity were 
measured in serum samples using Enzygnost® Anti Ru-
bella-Virus/ IgM and Enzygnost® Anti Rubella-Virus/ 
IgG (Dade Behring, Marburg, Germany), respectively, 
following the manufacturer’s instructions. 
Detection of rubella virus genomic RNA in amniotic 
fluid and urine was performed by ProDect RUBELLA 
and ProDect GEN.E.I.A (BSC Biotech S.p.A., Italy), 
following manifacturer’s instructions. Briefly the am-
plimers were hybridised with single-stranded DNA 
probes specific for Rubella virus and applied on to the 
walls of microtitre wells coated with streptavadin–bi-
otin.A DNA enzyme immunoassay was used to detect 
hybridised DNA; absorbance was measured photo-
metrically.
Results confirmation all samples were tested by RT-
PCR-Nested as previously described [14]. Traditional 
techniques were used for extraction (QIAamp Min Elute 
virus spin Kit, Qiagen, Milan, Italy) reverse transcrip-
tion and PCR nested reaction; amplified products were 
electrophoretically separated on 2% agarose gel (Roche 
Diagnostics GmbH, Mannheim, Germany). Gel was 
stained with ethidium bromide and visualized under UV 
light.
Results
Eighty-four serum samples and 11 amniotic liquid 
samples from 65 pregnant women were tested for IgM 
and IgG detection with avidity evaluation and virus 
detection, respectively. All women had undergone ru-
bella screening in other laboratories. Serum samples 
and urine from 18 newborn children with suspected 
infection, 10 born from mother followed by regional 
reference laboratory and 8 from women not previously 
tested by our centre, were analyzed; in particular, one of 
the children aged 7 months presented clinical manifesta-
tion consistent with CRS.
Demographic data, risk factors, clinical picture, vac-
cination, previous rubella disease, laboratory results of 
pregnant women and reasons of reference-laboratory 
access according to gestational week are reported in 
Table I. 
IgM reactivity or weak reactivity at the serological 
screening performed at the first level laboratory was ob-
served in 47 (72.3%) and 10 (15.4%) out of 65 mothers, 
respectively; 7(10.7%) seroconverted during pregnancy, 
9 (13.8%%) had rash and only one referred a contact 
with a suspected case. The gestational week average 
was 14.7 ± 0.71 and 80% mother accessed to the sec-
ond level laboratory between 5° and the 20° gestational 
week. It is noteworthy that 5 (10.7%) and 14 (29.8%) of 
the women, that resulted IgM reactive or weak reactive 
at the first level laboratory screening, performed the 
confirmation assay after the 21st gestational week and 
between 13 and 20th week, respectively.
Most of pregnant women (47, 72.3%) were asympto-
matic. Four out of 65 (6.2%) patients referred fever and 9 
(13.8%) presented rash associated or not with other symp-
toms such as fever, pharingodynia or artralgia (Tab. I).
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Nineteen women (29.2%) referred to be vaccinated 
against rubella but only one of them provided a cer-
tification. Five (7.7%) pregnant women referred past 
rubella infection without laboratory confirmation. Glo-
bally, 41 (63%) women were aware of being susceptible 
to rubella during pregnancy.
Twenty (30.8%) pregnant women continued the fol-
low-up in compliance with the flow-chart in Figure 
1. Among the 45 pregnant women that interrupted the 
follow-up, one aborted at the 11th gestational week 
because of a confirmed Cytomegalovirus (CMV) 
infection, one, which had exanthema, spontaneously 
aborted, one voluntary aborted, 8 women completed 
the pregnancy.
Eleven women IgM positive at the first visit, accessed to 
the laboratory for rash, seroconvertion or contact with a 
confirmed case, and underwent to amniocentesis at 21st-
23rd gestational week for rubella virus detection. only 
one out of 11 amniotic fluid analysed resulted positive 
for rubella virus RNA by PCR and for rubella virus iso-
lation on cell culture, supporting the diagnosis of acute 
rubella infection.
As regards newborns, 10 born from women followed 
by the reference laboratory during pregnancy were su-
bmitted to follow-up, that consist of monthly collection 
of blood and urine samples. Nine babies were normal 
with no evidence of CRI at birth and resulted negative 
either to IgM antibodies and viral molecular detection 
in urine samples. only one of ten presented cardiac 
anomalies at birth, but laboratory results confirmed that 
such abnormalities were not correlated with CRS. Eight 
newborn from mother monitored by other laboratories 
were followed during the first months of life. one out 
of 8 presented abnormalities at birth with diagnosis 
of psychomotor retard, myoclonia, hypotonia and su-
spected auditory deficit but serological and molecular 
pattern resulted negative for rubella. one of the children 
resulted IgM positive without clinical signs of CRS 
showed a decrease of IgM titres during follow-up and a 
negative PCR result. 
Discussion
To our knowledge this is one of the first studies that ex-
amines the role of a second level laboratory for rubella 
diagnosis in a Country, such as Italy, where the disease 
is under elimination. 
The laboratory survey of congenital rubella performed in 
Administrative Region Liguria presents some limitations 
and shows some improper practices during pregnancy 
follow-up. First of all, the survey didn’t have probably 
captured all the suspected cases of congenital rubella, 
according the case definition established by Health 
Ministry. Eversince, in Liguria, the 36.1% of women 
included in the age group 18-49 years is potentially 
Fig. 1. Flow-chart for pregnant women applied by regional reference laboratory.
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susceptible to rubella virus or are unaware of their im-
mune status, the annual number of pregnancies is around 
11,000 and the clinical specificity of the commercial 
rubella chemiluminescent IgM immunoassays tests rou-
tinely used by first level laboratories ranged between 
93.9% and 96.1%, the expected annual accesses to the 
second level laboratory in Liguria should reach 155 
patients [15-17]. Nevertheless during the 21-months of 
surveillance the accesses were only 65, showing that at 
least 100-120 women potentially resulted IgM-positive 
do not have a contact with reference laboratory. The rea-
sons of the missed second level diagnosis could be the 
lack of rubella screening or the underestimation of the 
IgM-positivity relevance during pregnancy follow-up. It 
is not possible to evaluate the role of the two improper 
practices, but unpublished data showed a high coverage 
of rubella screening during pregnancy. In any case, it 
appears necessary to implement actions 
to catch-up women that have poor contact 
with health system by the involvement and 
the collaboration of various health pro-
fessionals (pediatricians, gynaecologists, 
public health officers) and to provide ap-
propriate rubella educational information. 
Furthermore, the lack of rubella cases de-
tection has important public health effects 
making less sensible the survey system, 
postponing the alert signal. The reinforce 
of a warning system for early detection of 
rubella infection allows the adoption of all 
the activities useful to limit and stop viral 
spread and helping in achieving goals of 
rubella control and elimination. 
Moreover, this study highlighted that 
a high percentage of pregnant women 
performed the confirmation laboratory 
screening after the 21st gestational week, 
later than recommended in the WHo 
guidelines. The correct timing of sam-
pling together with complete information 
about the onset of clinical picture, vac-
cination status, risk factors for disease 
and epidemiological data obtained from 
patients, are needed for the correct inter-
pretation of the laboratory results and to 
achieve an accurate diagnosis, minimi-
zing anxiety for the patients, especial-
ly if pregnancy termination is conside-
red. Screening test on pregnant women 
should be performed before 8th gestation 
week, because after this period it’s very 
difficult to exclude a CRI in a suspected 
case. After infection or vaccination, spe-
cific IgM levels usually fall below the 
detection level within 2 months [18]. A 
IgM-negative and IgG-positive sample 
collected and analyzed by the second 
level laboratory after 8th gestation week 
in a pregnant previously resulted IgM 
positive or IgG negative at screening 
does not allow to exclude the infections in the first 
gestation weeks. IgM positive results at screening 
assay is quite frequent since heterotypic IgM antibody 
responses may occur in patients infected with other 
viruses, particularly EBV, and sera from these patients 
may give false positive results for rubella [15, 19-21]. 
Another of the most common causes for false positive 
reactions include the presence of rheumatoid factor, 
specific IgG, and non-specific, cross-reacting IgM in 
the samples. For these reasons, results from about 2% 
of serum samples tested for rubella IgM will be diffi-
cult to interpret, if and when the correct sampling time 
is respected [16].
At this regard, the determination of avidity for IgG may 
be useful as affinity is proportionally correlated with the 
age of the infection event. So a high avidity value that per-
sist over the time allows us to exclude a recent infection.
Tab. I. demographic data, risk factors, access reasons, clinical picture, vaccination, 
previous rubella disease, laboratory results of pregnant women and reasons of refe-
rence-laboratory access.
Mother (n. = 65)
Age (year, mean ± Sd) 30.74 ± 0.71
gestation period (week, mean ± Sd) 14.7 ± 0.71
Access Reason
Seroconvertion
igm positivity at the first visit
rash
Suspected or confirmed case contact
7 (10.8%)
48 (73.8%)
9 (13.9%)
1 (1.5%)
Clinical picture during pregnancy
Asimptomatic
Fever
rash
rash and fever
rash and pharingodynia
rash and artralgia
Artralgia
retronucal lymphadenopathy
47 (72.3%)
4 (6.2%)
6 (9.2%)
1 (1.5%)
1 (1.5%)
1 (1.5%)
4 (6.2%)
1 (1.5%)
Vaccination
Certified
referred by patient
no
unknown
1 (1.5%)
18 (27.7%)
29 (44.6%)
17 (26.2%)
Previous Rubella
Lab-confirmed
Suspected
no or unknown
0
5 (7.7%)
60 (92.3%)
Concomitant diseases
Cmv 1 (1.5%)
Follow-up: accesses
1
2
3 or more
45 (69.2%)
15 (23.1%)
5 (7.7%)
Children (n. = 18) Mother followed by reference lab
yes
no
10 (56.0%)
8 (44.0%)
First access (day, mean ± Sd) 47.8 ± 70.0
Follow-up: accesses
1
2
3 or more
8 (44.4%)
6 (33.3%)
4 (22.2%)
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Furthermore, about 70% pregnant women did not conti-
nue the follow-up so in many cases we were not able to 
obtain information about come measures. In the majori-
ty of cases the results of the first sample analyzed by the 
second level laboratory allowed us to exclude the chan-
ce of a previous infection and the follow-up completion 
represented an important feed-back for the evaluation of 
the laboratory performance.
In conclusion, results obtained in this study highlighted 
the need to maintain and implement rubella surveillance 
activities and to improve the management of pregnant 
women. At individual level clearly emerged the impor-
tance of the counselling offered to pregnant women hel-
ping them in deciding to continue or interrupt pregnancy 
and the need of providing appropriate rubella educatio-
nal information. Public health goals to rapidly reach are 
high levels of rubella vaccination coverage through vac-
cination of susceptible persons, the surveillance together 
with reporting implementation so to allow an appropriate 
and rapid response when a case of rubella is identified. 
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